HK1223098A1 - 杂芳基取代的吡唑 - Google Patents

杂芳基取代的吡唑 Download PDF

Info

Publication number
HK1223098A1
HK1223098A1 HK16111252.2A HK16111252A HK1223098A1 HK 1223098 A1 HK1223098 A1 HK 1223098A1 HK 16111252 A HK16111252 A HK 16111252A HK 1223098 A1 HK1223098 A1 HK 1223098A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
hydrogen
formula
compound
methyl
Prior art date
Application number
HK16111252.2A
Other languages
English (en)
Chinese (zh)
Inventor
Anne Mengel
Marion Hitchcock
Anja Richter
Lars BÄRFACKER
Hans Briem
Gerhard Siemeister
Wilhelm Bone
Amaury Ernesto FERNÁNDEZ-MONTALVÁN
Jens SCHRÖDER
Simon Holton
Cornelia PREUSSE
Ursula MÖNNING
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of HK1223098A1 publication Critical patent/HK1223098A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16111252.2A 2013-06-21 2014-06-17 杂芳基取代的吡唑 HK1223098A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13173298 2013-06-21
EP13173298.4 2013-06-21
PCT/EP2014/062689 WO2014202584A1 (en) 2013-06-21 2014-06-17 Heteroaryl substituted pyrazoles

Publications (1)

Publication Number Publication Date
HK1223098A1 true HK1223098A1 (zh) 2017-07-21

Family

ID=48651939

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111252.2A HK1223098A1 (zh) 2013-06-21 2014-06-17 杂芳基取代的吡唑

Country Status (8)

Country Link
US (1) US9745285B2 (enExample)
EP (1) EP3010901B1 (enExample)
JP (1) JP2016525075A (enExample)
CN (1) CN105452237A (enExample)
CA (1) CA2916194A1 (enExample)
ES (1) ES2652305T3 (enExample)
HK (1) HK1223098A1 (enExample)
WO (1) WO2014202584A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
ES2638144T3 (es) 2011-12-21 2017-10-18 Bayer Intellectual Property Gmbh Bencilpirazoles sustituidos
US20160046604A1 (en) * 2013-03-21 2016-02-18 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
CN105452242A (zh) * 2013-06-21 2016-03-30 拜耳制药股份公司 杂芳基取代的吡唑
WO2014202590A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
US9682974B2 (en) 2013-10-30 2017-06-20 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
US10428044B2 (en) 2014-06-17 2019-10-01 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
CR20170100A (es) 2014-09-19 2017-04-24 Bayer Pharma Aktiengesellchaft Indazoles sustituidos con bencilo como inhibidores bub1
EA032530B1 (ru) 2015-01-28 2019-06-28 Байер Фарма Акциенгезельшафт 4h-пирроло[3,2-c]пиридин-4-оновые производные
US10227299B2 (en) 2015-06-17 2019-03-12 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
US20230364070A1 (en) 2020-09-23 2023-11-16 Scorpion Therapeutics, Inc. Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer
TW202229282A (zh) 2020-09-30 2022-08-01 美商史考皮恩治療有限公司 治療癌症之方法
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
EP4225445A2 (en) 2020-10-09 2023-08-16 Scorpion Therapeutics, Inc. Heterocyclic inhibitors of egfr and/or her2, for use in the treatment of cancer
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
WO2024254266A1 (en) 2023-06-08 2024-12-12 Scorpion Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
WO2024254298A1 (en) 2023-06-08 2024-12-12 Scorpion Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863282B2 (en) * 2003-03-14 2011-01-04 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20120232062A1 (en) 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
EP2560966B1 (en) 2010-03-30 2021-01-06 Verseon International Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
EA026692B1 (ru) * 2010-06-30 2017-05-31 Айронвуд Фармасьютикелз, Инк. Стимуляторы sgc
UA111754C2 (uk) * 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
ES2638144T3 (es) 2011-12-21 2017-10-18 Bayer Intellectual Property Gmbh Bencilpirazoles sustituidos
EP2797915B1 (en) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
WO2013167698A1 (en) 2012-05-11 2013-11-14 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2907592A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
US20160046604A1 (en) 2013-03-21 2016-02-18 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
EP2976334A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted indazoles
CN105452242A (zh) 2013-06-21 2016-03-30 拜耳制药股份公司 杂芳基取代的吡唑
JP2016522231A (ja) 2013-06-21 2016-07-28 バイエル ファーマ アクチエンゲゼルシャフト ジアミノヘテロアリール置換ピラゾール類
CA2916097A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
WO2014202590A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
US9682974B2 (en) 2013-10-30 2017-06-20 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
US20170275270A1 (en) 2014-09-19 2017-09-28 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles
WO2016042081A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
CR20170100A (es) 2014-09-19 2017-04-24 Bayer Pharma Aktiengesellchaft Indazoles sustituidos con bencilo como inhibidores bub1
JP2017535514A (ja) 2014-09-19 2017-11-30 バイエル ファーマ アクチエンゲゼルシャフト Ｂｕｂ１キナーゼ阻害薬としてのベンジル置換インダゾール類

Also Published As

Publication number Publication date
JP2016525075A (ja) 2016-08-22
EP3010901A1 (en) 2016-04-27
ES2652305T3 (es) 2018-02-01
US9745285B2 (en) 2017-08-29
US20160145238A1 (en) 2016-05-26
EP3010901B1 (en) 2017-09-13
CA2916194A1 (en) 2014-12-24
CN105452237A (zh) 2016-03-30
WO2014202584A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
HK1223098A1 (zh) 杂芳基取代的吡唑
CN104411701B (zh) 作为Bub1抑制剂的用于治疗癌症的取代的环烯并吡唑
HK1218750A1 (zh) 3-杂芳基取代的吲唑
HK1223097A1 (zh) 杂芳基取代的吡唑
HK1223350A1 (zh) 杂芳基取代的吲唑
HK1222852A1 (zh) 二氨基杂芳基取代的吡唑
CN104125957A (zh) 取代的苄基吡唑
HK1221717A1 (zh) 取代的苄基吡唑
HK1222846A1 (zh) 取代的苄基吡唑
HK1217324A1 (zh) 二氨基杂芳基取代的吲唑
HK1226733A1 (en) Heteroaryl substituted pyrazoles
HK1203196B (en) Substituted benzylpyrazoles